DUBLIN--(BUSINESS WIRE)--The "Osteonecrosis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Osteonecrosis is bone death caused by poor blood supply to the area. It is most common in the hip and shoulder, but can affect other large joints such as knee, elbow, wrist and ankle. Osteonecrosis can be caused by disease, or a severe trauma, such as a break or dislocation, that affects the blood supply to the bone. There are no symptoms in the early stages. Symptomatic treatment is available.
Osteonecrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteonecrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteonecrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively.
Osteonecrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Osteonecrosis - Overview
- Osteonecrosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Osteonecrosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Osteonecrosis - Companies Involved in Therapeutics Development
- Bone Therapeutics SA
- Enzo Biochem Inc
- K-Stemcell Co Ltd
For more information about this report visit https://www.researchandmarkets.com/research/694m5q/osteonecrosis
